؉ T lymphocytes (T CD8 ) against cancer is often limited by the development of peripheral tolerance toward the dominant tumor-associated Ags. Because multiple epitopes derived from a given tumor Ag (T Ag) can be targeted by T CD8 , vaccine approaches should be directed toward those T CD8 that are more likely to survive under conditions of persistent Ag expression. In this study, we investigated the effect of peripheral tolerance on the endogenous T CD8 response toward two epitopes, designated epitopes I and IV, from the SV40 large T Ag. Using rat insulin promoter (RIP) 1-Tag4 transgenic mice that express T Ag from the RIP and develop pancreatic insulinomas, we demonstrate that epitope IV-but not epitope I-specific T CD8 are maintained long term in tumor-bearing RIP1-Tag4 mice. Even large numbers of TCR-transgenic T cells specific for epitope I were rapidly eliminated from RIP1-Tag4 mice after adoptive transfer and recognition of the endogenous T Ag. Importantly, immunization of RIP1-Tag4 mice at 5 wk of age against epitope IV resulted in complete protection from tumor progression over a 2-year period despite continued expression of T Ag in the pancreas. This extensive control of tumor progression was associated with the persistence of functional epitope IV-specific T CD8 within the pancreas for the lifetime of the mice without the development of diabetes. This study indicates that an equilibrium is reached in which immune surveillance for spontaneous cancer can be achieved for the lifespan of the host while maintaining normal organ function.
A variety of experimental models have been used to examine the role of CD8 ϩ T lymphocytes (T CD8 ) 5 in the immunotherapy of tumors. These models include transplantable tumors as well as spontaneously arising tumors that develop in transgenic mice expressing cell-or virus-derived oncogenes. Such studies have revealed a multitude of factors that may inhibit an effective T CD8 -mediated response against the tumor (reviewed in Ref. 1), including but not limited to the deletion of tumor-specific T CD8 by central tolerance (2) (3) (4) (5) or their inactivation by peripheral tolerance (6 -8) . Mechanisms that allow the tumor to resist even an active T CD8 response also contribute to failed immunotherapy of cancer, such as the inability of tumor-specific T CD8 to access the tumor (9) . Some experimental models have used surrogate tumor Ags (T Ags) expressed in transplantable and transgene-induced tumors to monitor the role of endogenous T CD8 in the control of tumor growth (5, 10 -12) or, alternatively, have assessed the response of T CD8 derived from TCR transgenic mice toward transplantable or oncogene-induced spontaneous tumors (13) (14) (15) (16) (17) . Few studies, however, have assessed the role of the endogenous natural T CD8 for the control of spontaneous tumors expressing a known tumor Ag (18 -22) .
T CD8 recognize peptides bound to MHC class I molecules on the tumor cell surface. These peptides are derived from the processing of intracellular proteins, with each MHC class I allele binding different combinations of the available peptides for presentation at the cell surface (23) . Thus, a wide variety of peptide/MHC complexes is presented at the tumor cell surface, and the tumor-specific T CD8 response can be targeted against multiple epitopes simultaneously, although with varying efficiencies (24) . This phenomenon, known as immunodominance, is controlled by multiple factors affecting Ag processing and presentation as well as the T cell repertoire of the host (25) . Because multiple tumor epitopes could potentially be targeted, assessing the nature of the immune response toward epitopes that lead to the most effective control of tumor progression in experimental models will provide clues toward better approaches to the immunotherapy of cancer.
Our previous studies using two different transgenic mouse lines expressing SV40 large tumor Ag (T Ag) indicate that immunodominance among T Ag epitopes contributes toward the efficiency of T CD8 -mediated control of progressively growing tumors due to differential inactivation of T Ag-specific T CD8 (3, 6) . SV40 T Ag encodes four H-2 b -restricted epitopes (26) . Epitopes I (residues 206 -215), II/III (residues 223-231), and V (residues 489 -497) are H-2D b (Db)-restricted, whereas epitope IV (residues 404 -411) is H-2K b (Kb)-restricted. These four T Ag-derived, T CD8 -recognized epitopes fall on a hierarchical scale, with epitope IV being the most immunodominant followed by epitopes I and II/III (27, 28) . Epitope V is immunorecessive and not immunogenic unless the three dominant epitopes are inactivated in T Ag (29, 30) . The ability of T CD8 -specific for T Ag to control tumor progression was established by showing that the transfer of T CD8 specific for the immunodominant T Ag epitopes into SV11 T Ag transgenic mice induced regression of advanced stage spontaneous tumors (31) .
To better understand the role of the endogenous T CD8 repertoire in the control of spontaneous tumor progression, we took advantage of the well-characterized tumor model of rat insulin promoter (RIP) 1-Tag4 transgenic mice on the C57BL/6 (B6) background (32) . In RIP1-Tag4 mice, T Ag is expressed as a transgene from the rat insulin II promoter in pancreatic ␤ cells, which leads to highly predictable formation of ␤ cell tumors. The transformation of ␤ cells by T Ag is a gradual process, initially inducing development of islet hyperplasia by three months of age and followed by the appearance of macroscopic insulinomas between 5 and 6 mo of age (18, 33) . The average life span of RIP1-Tag4 mice is ϳ200 days, with 100% of mice developing tumors. Transformed ␤ cells secrete high amounts of insulin leading to the development of hypoglycemic shock and death of tumor-bearing mice. Previously, Knowles and colleagues (18) demonstrated that immunization of RIP1-Tag4 mice with SV40 before or during T Ag-induced tumorigenesis resulted in the development of T CD8 capable of lysing syngeneic T Ag-transformed cells in vitro. However, only immunization before the expression of T Ag in the ␤ cells (at 3 wk of age) led to long-term protection against tumor development. Whether the composition of T Ag-specific T CD8 response was altered by expression of the endogenous T Ag was not addressed. Although this previous study demonstrated that the presence of T Ag-specific T CD8 is associated with long-term control of tumor progression in RIP1-Tag4 mice, it remained to be determined whether peripheral tolerance limits T CD8 responding to individual T Ag epitopes over the course of tumor progression and whether long-term protection from tumor progression is associated with a particular T Ag epitope.
Our results show that activation of endogenous T CD8 specific for the dominant SV40 T Ag epitope IV before T Ag expression in the pancreatic ␤ cells leads to lifelong surveillance against T Ag-induced spontaneous tumors. Importantly, functional epitope IVspecific but not epitope I-specific T CD8 persist in the host without inducing tissue destruction or diabetes in RIP1-Tag4 mice.
Materials and Methods

Mice
B6 (H-2 b ) mice were purchased from The Jackson Laboratory, and B6.SJL mice (CD45.1 ϩ ) were procured from Taconic Farms. Line RIP1-Tag4 mice are on the B6 background and express the SV40 early region as a transgene under control of the rat insulin promoter and were described previously (32) . TCR-I mice express epitope I-specific TCR␣ and TCR␤-chains as a transgene (15) and are available from The Jackson Laboratory as line B6.Cg-Tg(Tcra TcrB)416Tev/J. Approximately 95% of T CD8 express the TCR transgenes. All mice were maintained at the animal facility of the Milton S. Hershey Medical Center (Hershey, PA). Animal studies were performed in accordance with guidelines established by the Pennsylvania State University College of Medicine Institutional Animal Care and Use Committee (Hershey, PA) under an approved protocol.
Reagents and immunizations
The B6/WT-19 cell line was derived previously by transformation of B6 mouse embryo fibroblasts with wild-type SV40 strain VA45-54 (34) . B6/ 15Bb cells express a T Ag variant in which epitopes I, II/III, and V have been inactivated by site-directed mutagenesis but which encodes wild-type epitope IV (27) . Cell lines were maintained in DMEM supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, 100 g/ml kanamycin, 2 M L-glutamine, 10 mM HEPES, 0.075% (w/v) NaHCO 3 , and 5-10% FBS. Peptides were synthesized at the Macromolecular Core Facility of the Milton S. Hershey Medical Center by Fmoc chemistry using an automated peptide synthesizer (9050 MilliGen PepSynthesizer; Millipore). Peptides used in these experiments correspond to the SV40 T Ag epitope I (SAIN NYAQKL; 206 -215), epitope IV containing a Leu replacement of Cys at residue 411 (VVYDFLKL; 404 -411), and an epitope from HSV glycoprotein B (gB) (SSIEFARL; 498 -505). Immunization of mice with T Agexpressing cell lines was conducted by i.p. injection of 3-5 ϫ 10 7 cells in 0.5 ml of HBSS at the indicated ages.
Flow cytometric analysis and in vitro stimulation of bulk CTL cultures
Ex vivo staining of T CD8 with MHC tetramers and primary conjugated Abs was performed on single-cell suspensions prepared from spleens as described previously (27) . For dissociation of tumors and pancreas, tissue was minced with a razor blade and incubated in HBSS containing 1% FBS, 1 mg/ml collagenase D (Roche), and 50 U/ml DNase I (Roche) for 1 h at 37°C. Any remaining clumps were dissociated by gentle pipetting, and cells were washed before tetramer staining. In some cases, spleen cells were cultured in vitro for 6 days in the presence of ␥-irradiated B6/WT-19 stimulator cells as described previously (3) . After staining, cells were fixed with 2% paraformaldehyde in PBS and analyzed using a FACScan or FACSCalibur flow cytometer (BD Biosciences). Data were analyzed using FlowJo software (Tree Star). Production and characterization of the Db/T Ag epitope I (Db/I), Kb/T Ag epitope IV (Kb/IV), Db/influenza virus (Flu) nucleoprotein (NP) epitope 366 -374 (Db/Flu), and Kb/HSV gB epitope 498 -505 (Kb/gB) tetramers were described previously (27) . The following mAbs were purchased from BD Pharmingen: PE-and CyChrome-labeled rat anti-CD8␣ (clone 53-6-7), FITC-labeled rat anti-mouse IFN-␥ (clone XMG1.2), and PE-labeled anti-mouse CD45.1 (clone A20). The percentage of CD8 ϩ cells that stained positive for the T Ag-specific tetramer was determined by subtracting the percentage of cells that stained positive with the control Db/Flu or Kb/gB tetramers within the same population.
Adoptive transfer and proliferation assay
Adoptive transfers were performed using sex-matched, RBC-depleted lymphocytes derived from spleens and lymph nodes of TCR-I transgenic mice. Recipient mice received i.v. injections of lymphocytes derived from spleen and lymph nodes of TCR-I mice that contained 1-2 ϫ 10 6 clonotypic CD8 ϩ T cells as determined by prior staining with MHC tetramers. Mice were immunized the following day. For proliferation assays, TCR-I-derived lymphocytes were labeled with 5 M CFSE (Invitrogen Life Sciences) for 10 min at 37°C in PBS and 0.1% BSA followed by three washes before i.v. injection into recipient mice. Proliferating cells were detected after three days by measuring the mean fluorescent intensity of CFSE staining retained in CD8
ϩ Db/I tetramer-positive cells recovered from the spleens of recipient mice.
Intracellular cytokine assays
For staining of intracellular IFN-␥, RBC-depleted lymphocyte suspensions were prepared as described above and incubated at 5 ϫ 10 6 /ml with the indicated synthetic peptides (1 M) representing T Ag or control epitopes and 1 g/ml brefeldin A in complete RPMI 1640 containing 10% FBS for 4 h at 37°C in 5% CO 2 . The Cytofix/Cytoperm kit (BD Pharmingen) was used to stain for IFN-␥ production according to the manufacturer's instructions and as described previously (27) . For peptide titration assays, splenocytes from B6/WT-19-immunized mice were restimulated in vitro with ␥-irradiated B6/WT-19 cells for 5 days at 37°C with 5% CO 2 . Responder cells were plated at 5 ϫ 10 5 cells/well in the presence of titrated amounts of the epitope IV or control K b -binding peptide 498 -505 from HSV gB (35) and 1 g/ml brefeldin A. After a 6-h incubation at 37°C with 5% CO 2 , cultures were stained as described above. 
In vivo cytotoxicity assay
Tumor histology, immunohistochemistry, and measurement of islet size
For T Ag immunohistochemistry, pancreata were fixed with 10% buffered formalin before being embedded in paraffin blocks. Eight-micrometer-thick sections were cut on a microtome and collected onto positively charged slides. Sections were deparaffinized in xylene and rehydrated in ethanol. After two washes in PBS, slides were treated with Ag-unmasking solution (Vector Laboratories) for 30 min in a steamer. Cooled slides were washed in PBS, incubated with 10% normal goat serum in PBS containing 0.1% Tween 20 for 30 min, and washed and incubated with primary anti-T Ag Ab for 1 h at room temperature. Primary Ab consisted of an equal mixture of mAb Pab419 (36) and Pab901 (37) , culture supernatants that bind to epitopes in the amino-terminal and carboxyl-terminal portions of SV40 T Ag, respectively. Sections were then incubated for 1 h with biotinylated anti-mouse Ab and visualized with peroxidase/diaminobenzidine detection (ChemMate detection kit; Ventana) for 2-10 min, as needed. Parallel sections were stained with H&E. Sections were examined using a Nikon Microphot-FXA microscope, and representative images were captured using a Sony DKC-ST5 digital camera. To measure the size of individual islets, H&E-stained pancreatic sections were examined under the microscope using a micrometer. The radius of all islets per section was measured, and their individual sizes were plotted. Ten sections were examined for each mouse.
Life span analysis and measurement of blood glucose levels
Mice in life span analyses were monitored for symptoms of hypoglycemia, which are indicative of advanced stage tumors, and sacrificed when blood glucose levels dropped below 50 mg/dl. Blood glucose levels were measured using an Elite glucometer (Bayer). Kaplan-Meier survival plots were constructed using Prism software (GraphPad).
Results
RIP1-Tag4 mice with progressively growing tumors remain responsive to T Ag epitope IV but not to T Ag epitope I
To determine whether T CD8 specific for the immunodominant T Ag epitopes remain sensitive to immunization in aged RIP1-Tag4 mice, groups of three RIP1-Tag4 mice aged 35, 90, and 180 days as well as 90-day-old B6 mice were immunized i.p. with T Agtransformed B6/WT-19 cells that express wild-type T Ag. Nine days later, splenic T CD8 lymphocytes were stained with anti-CD8 Ab and MHC class I tetramers capable of detecting T cells specific for epitope I (Db/I) or epitope IV (Kb/IV). A tetramer composed of the influenza NP epitope NP 366 -374 (Db/Flu) was used as a control tetramer. The data in Fig. 1A show that epitope IV-specific T cells expanded in 35-day-old RIP1-Tag4 mice to levels similar to those for the control B6 mice. The number of epitope IV-specific T CD8 recruited by immunization gradually declined in older RIP1-Tag4 mice but remained significant even at 180 days of age. In contrast, the T CD8 response against epitope I already was decreased in 35-day old RIP1-Tag4 mice compared with B6 mice and was undetectable by tetramer staining in 180-day-old RIP1-Tag4 mice.
We determined whether T Ag-specific T CD8 recruited by immunization with B6/WT-19 cells localized to the tumors in older RIP1-Tag4 mice. Groups of 180-day-old RIP1-Tag4 mice were immunized with B6/WT-19 cells. Nine days later, tumors were enzymatically digested and epitope-specific T CD8 were directly enumerated by staining with MHC tetramers. The data in Fig. 1B show that epitope IV-specific T CD8 (29% of total T CD8 ) infiltrated the pancreatic tumors. In parallel experiments we found that approximately half the number of Kb/IV tetramer-positive T CD8 detected in the tumor at this time point were capable of producing IFN-␥ in response to short-term incubation with epitope IV peptide as determined by intracellular cytokine staining (data not shown). Staining of tumor-derived T CD8 with the Db/I tetramer did not show positive cells above the background staining obtained with control Db/Flu tetramer. These results show that a proportion of epitope IV-specific but not epitope I-specific T CD8 survive peripheral tolerance in tumor-bearing RIP1-Tag4 mice and remain responsive to immunization, resulting in the infiltration of pancreatic tumors.
Epitope I-specific TCR transgenic T cells are rapidly tolerized in RIP1-Tag4 mice
Following T Ag immunization of 5-wk-old naive RIP1-Tag4 mice, the response to epitope IV is ϳ15-fold greater than that directed toward epitope I (Fig. 1 ). Whether this difference can be traced to fewer precursors in the naive T cell repertoire targeting epitope I vs epitope IV is unknown. If such a discrepancy exists, however, the time required to induce tolerance among epitope I-specific T CD8 vs epitope IV-specific T CD8 may be significantly shorter. To determine whether an increased frequency of epitope I-specific T CD8 would lead to a more enduring response in RIP1-Tag4 mice, we used adoptive transfer of naive T CD8 from epitope I-specific TCR transgenic mice in which Ͼ95% of the T CD8 are specific for epitope I (15) . In a previous study, TCR-I transgenic T cells were shown to be triggered by the endogenous T Ag after transfer into mice expressing T Ag as a transgene from the ␣-amylase promoter (15) . To monitor the consequences of TCR-I T cell transfer into RIP1-Tag4 mice, CFSE-labeled TCR-I-derived lymphocytes were transferred into RIP1-Tag4 mice at various ages representing the various stages of tumor progression. The ability of the transferred T CD8 to proliferate in response to the endogenous T Ag was monitored after 3 days. The frequency of TCR-I cells detected in the spleens of RIP1-Tag4 mice increased slightly over that detected in B6 mice, with the highest number of cells detected in 6-mo-old RIP1-Tag4 mice ( Fig. 2A, upper panels) . This increase corresponded with the presence of proliferating cells in the RIP1-Tag4 mice ( Fig. 2A, bottom panels) . Although TCR-I T cells initially proliferated in RIP1-Tag4 mice, these cells were rapidly eliminated by day 10 as evidenced by only minimal detection in the spleen (Fig. 2B) and lack of detection in the pancreas (data not shown) of 6-mo-old mice. Similar results were obtained when TCR-I cells were transferred into younger mice (data not shown). These results indicate that epitope I-specific TCR transgenic T CD8 are rapidly activated and eliminated from RIP1-Tag4 hosts following recognition of the endogenous T Ag, consistent with loss of the endogenous population of epitope I-specific T CD8 .
We next determined whether immunization could delay the loss of TCR-I T cells from RIP1-Tag4 hosts. At 3 mo of age, epitope I-specific T CD8 represent ϳ1% of splenic T CD8 following immunization of RIP1-Tag4 mice (Fig. 1A) . This level was increased to 9.5% of T CD8 following adoptive transfer with TCR-I cells and subsequent immunization (Fig. 2C) , a level comparable to that of the epitope IV-specific T CD8 that accumulate from the endogenous T cell repertoire ( Fig. 1A; 3 mo) . We noted that 2.5-fold more epitope I-specific T CD8 accumulated in the spleens of B6 mice compared with RIP1-Tag4 mice following adoptive transfer of TCR-I cells and immunization (Fig. 2C) . By 40 days postimmunization, epitope I-specific T CD8 had decreased below the limit of detection by tetramer analysis in RIP1-Tag4 mice but represented 5% of CD8 ϩ cells in B6 mice, a 5-fold decrease from day 10. To determine whether a residual population of TCR-I T cells was present in RIP1-Tag4 mice at this later time point, some mice were given a booster immunization with B6/WT-19 cells at day 34, 6 days before analysis. The results demonstrate that epitope I-specific T CD8 remained undetectable in RIP1-Tag4 mice despite extensive expansion in B6 mice. Thus, immunization successfully induces the expansion of TCR-I T cells in RIP1-Tag4 mice leading to initial accumulation at levels similar to that obtained with the endogenous epitope IV-specific T CD8 , but these T CD8 fail to persist long term despite this increased frequency.
Early immunization of RIP1-Tag4 mice against epitope IV prevents the development of tumors without inducing diabetes
Because we observed that T CD8 specific for epitope IV but not epitope I could be triggered even in tumor-bearing RIP1-Tag4 mice (Fig. 1A) , we determined whether specific immunization against the immunodominant epitope IV alone could mediate control of tumor progression in RIP1-Tag4 mice. A group of 35-dayold RIP1-Tag4 mice were immunized i.p. with B6/15Bb cells expressing a T Ag variant (epitope IV-only) containing epitope IV but lacking the other H-2 b -restricted epitopes I, II/III, and V (27) .
Immunization with B6/15Bb cells results in a quantitatively similar T CD8 response to epitope IV as observed following immunization with B6/WT-19 cells expressing the wild-type T Ag (data not shown). Another group of RIP1-Tag4 mice was immunized at 180 days of age and survival was monitored. The data in Fig. 3A demonstrate that early immunization at 35 days of age with epitope IV-only T Ag-expressing cells prevented the progression of tumors, because all mice in the group (n ϭ 8) lived for two years, at which time these mice were euthanized for further analysis (see below). In contrast, immunization of RIP1-Tag4 mice with epitope IV-only T Ag-expressing cells at 180 days of age was not effective at controlling tumor progression (n ϭ 8, median 204 days), and their life span was similar to untreated RIP1-Tag4 mice (n ϭ 10, median 194 days). Thus, immunization of RIP1-Tag4 mice at 35 days of age against epitope IV results in a normal disease-free life span, whereas immunization of tumor-bearing mice had a minimal effect on survival.
To monitor the effect of immunization on tumor growth, we measured the size of individual islets at various ages in RIP1-Tag4 mice that remained unimmunized (Fig. 3C ) or were immunized with IV-only T Ag-expressing cells at 35 days of age (Fig. 3D) . Increased islet size in unimmunized RIP1-Tag4 mice can be detected as early as 84 days of age, which is consistent with the reported development of initial islet hyperplasia (38) . Islet size further increased by 175 days of age, corresponding with the appearance of macroscopic tumors. Histological analysis on days 180 and 720 of pancreata from immunized RIP1-Tag4 mice (Fig. 3D) revealed only modest hyperplasia with islet sizes similar to that found in normal B6 mice, although small tumors could be detected in some mice (1-1.5-mm in diameter). Thus, the protective effect of early immunization against epitope IV correlates with inhibition of tumor development in RIP1-Tag4 mice.
Immunization against the T Ag might be expected to induce an autoimmune phenotype and subsequent diabetes if ␤ cells are specifically destroyed by responding immune cells as has been observed in similar transgenic models (39, 40) . However, we found that mice immunized with B6/15Bb cells at 5 wk of age that survived long term maintained normal levels of blood glucose (Fig.  3B) , indicative of continued ␤ cell function. In contrast, naive RIP1-Tag4 mice became hypoglycemic by 27 wk of age, consistent with the progression of ␤ cell tumors producing high levels of insulin (32) . Thus, immunization against T Ag epitope IV results in continuous and long-term protection from tumor progression without disrupting pancreatic function.
Immunized RIP1-Tag4 mice survive long term despite continued expression of T Ag
Long-term survival of RIP1-Tag4 mice immunized with T Agtransformed cells at 35 days of age could be explained by the loss of ␤ cells expressing the T Ag transgene. To assess this possibility, we determined whether long-term surviving RIP1-Tag4 mice that were immunized at 35 days of age maintain T Ag expression in the pancreatic islets as detected by immunohistochemistry (Fig. 4) . Islet cells from unimmunized B6 mice lacked T Ag expression (Fig. 4C) , whereas the majority of cells in the islets of 6-mo-old naive RIP1-Tag4 mice were positive for T Ag expression (Fig.  4D) . We then analyzed pancreatic tissue obtained from long-term surviving RIP1-Tag4 mice that were immunized at 35 days of age. The histological analysis of pancreatic sections revealed that T Ag-positive cells were detected in the islets of 1-year-old (Fig. 4 , G and H) and 2-year-old (Fig. 4 , K and L) RIP1-Tag4 mice. H&E staining of pancreatic tissue from these T Ag-immune mice showed that most islets were smaller than the islets found in naive 6-mo-old RIP1-Tag4 mice, although some hyperplastic islets were slightly larger (Fig. 4F) . It should be noted that the number of islet cells positive for T Ag from immunized mice was generally reduced (Fig. 4 , G, K, and L) compared with the number of T Agpositive cells detected in tumors from unimmunized RIP1-Tag4 mice (Fig. 4D ) unless a particular islet appeared hyperplastic (Fig.  4H) . Hyperplastic islets were rare, however, in immunized mice (Fig. 3D) . Thus, despite continuous expression of T Ag in the islets, large tumors did not develop in immunized mice. These results demonstrate that immunization at 35 days of age with T Ag epitope IV-only expressing cells prevented the development of tumors in RIP1-Tag4 mice. These data also suggest that T Ag-expressing islet cells may be susceptible to T CD8 -mediated elimination but that enough ␤ cells persist to produce insulin over the lifespan of the mice.
Lifelong persistence of T Ag epitope IV-specific T CD8 in immunized RIP1-Tag4 mice
We next determined whether epitope IV-specific T CD8 induced by immunization with Tag IV-only cells at 35 days of age persist and remain functional in 2-year old RIP1-Tag4 survivor mice. Representative survivors were sacrificed to quantitate the epitope IVspecific T CD8 present in the spleens and pancreas by tetramer staining and to examine T cell function by in vivo cytotoxicity assay (Fig. 5A ). This analysis revealed that epitope IV-specific T CD8 were present at detectable levels in the spleens (8.1% of total T CD8 ) of long-term survivors and expanded dramatically (53% of total T CD8 ) following in vitro culture ( Fig. 5A; group 5) . Analysis of epitope IV-specific in vivo cytotoxicity in the same animal showed that epitope IV-pulsed targets were completely eliminated. To determine whether these persisting epitope IV-specific T CD8 could expand following antigenic challenge in vivo, representative mice were immunized with B6/WT-19 cells. After nine days, epitope IV-specific T CD8 had expanded to 15% of T CD8 in the spleen ( Fig. 5A; group 6 ), indicating that these persisting T CD8 remained sensitive to antigenic challenge. Epitope IV-pulsed target cells were also completely eliminated in these mice although no epitope I-specific lysis was detected, indicating that these RIP1-Tag4 mice remained fully tolerant to epitope I despite the lack of tumor progression. Thus, in contrast to the fate of epitope I-specific T CD8 , epitope IV-specific T CD8 primed from the endogenous repertoire by specific immunization persist long term in RIP1-Tag4 mice and remain functional even in aged mice.
For continuous inhibition of tumor growth to occur, epitope IVspecific T CD8 induced by immunization should be present in the pancreas of long-term surviving RIP1-Tag4 mice. Thus, we analyzed by tetramer staining enzymatically digested pancreata from 1-year-old RIP1-Tag4 mice immunized with epitope IV-only T Ag expressing B6/15Bb cells at 35 days of age. The data in Fig. 5B demonstrate that 7.4% of T CD8 in the pancreas stained positively with the Kb/IV tetramer at this late time point. Similarly, a slightly lower number (6.3%) of Kb/IV tetramer-positive T CD8 were detected in the spleen. In contrast, lymphocytes isolated from the spleen and pancreas of a naive 6-mo-old RIP1-Tag4 mouse were devoid of epitope IV-specific T CD8 , indicating that T cell accumulation in the pancreas requires specific immunization. Taken together, our data clearly show that epitope IV-specific T CD8 persist in the spleens and pancreas of RIP1-Tag4 mice immunized at 35 days of age and remain functional throughout the lifetime of the mice without being significantly tolerized.
Epitope IV-specific T CD8 activated in tumor-bearing mice are not functionally compromised
One possible explanation for the inability of immunization against T Ag to induce control of advanced-stage tumors in RIP1-Tag4 mice is that the responding epitope IV-specific T CD8 in older mice are rendered anergic or that higher avidity T CD8 are deleted following recognition of self Ag (7, 15, 41-43) . Thus, we determined whether RIP1-Tag4 mice immunized at 6 mo of age could eliminate target cells pulsed with epitope IV peptide. Epitope IV-specific T CD8 were recruited to 2.2% of T CD8 following immunization of 171-day-old RIP1-Tag4 mice with wild-type T Ag-expressing B6/WT-19 cells ( Fig. 5A; group 4) . In addition, epitope IV-pulsed targets were completely eliminated in the in vivo killing assay, whereas no significant lysis of epitope I-pulsed target cells was observed. In contrast, both epitope I-specific and IV-specific killing was detected in control B6 mice immunized with B6/WT-19 cells ( Fig. 5A; group 2) . We considered that because epitope IVspecific T CD8 persisted in 6-mo-old naive RIP1-Tag4 mice, some spontaneous priming against the T Ag in tumor-bearing RIP1-Tag4 mice might occur. Spleen cells from unimmunized 6-mo-old RIP1-Tag4 mice were analyzed directly by tetramer staining. The results in Fig. 5A (group 3) show that although epitope IV-specific T CD8 were not detected directly ex vivo by MHC tetramer analysis, a modest level of epitope IV-specific killing was detected (39%). Moreover, epitope IV-specific T CD8 were expanded after in vitro culture (6.2% of T CD8 ), indicating that RIP1-Tag4 mice spontaneously develop low numbers of activated epitope IV-specific T CD8 , a finding consistent with those reported by Ye et al. (18) in which SV40-specific CTL activity was detected ex vivo. No epitope IV-specific T CD8 were detected following in vitro culture of splenocytes from naive B6 mice ( Fig. 5A; group 1) . Thus, the T CD8 triggered by immunization in tumor-bearing RIP1-Tag4 mice remain functional in vivo. To determine whether the avidity of epitope IV-specific T CD8 was altered in tumor-bearing RIP1-Tag4 mice, we immunized groups of 2-mo-old and tumor-bearing 8.5-mo-old RIP1-Tag4 mice as well as nontransgenic B6 mice with B6/WT-19 cells expressing wild-type T Ag. After 10 days, spleen cells were harvested and cultured for 5 days in vitro with irradiated B6/WT-19 cells to expand the low number of cells that are detected in the older RIP1-Tag4 mice (Fig. 1) . All mice in the 8.5-mo-old group had extensive tumor burden, whereas those in the 2-mo-old group lacked detectable tumors (data not shown). Cells in the responding lymphocyte cultures were tested for their ability to produce IFN-␥ in response to titrated amounts of epitope IV peptide in an intracellular cytokine assay. The results demonstrate that T CD8 derived from tumor-bearing RIP1-Tag4 mice recognized epitope IV peptide as efficiently as those derived from 2-mo-old RIP1-Tag4 mice (Fig. 6 ). In addition, the avidity of epitope IV-specific T CD8 derived from RIP1-Tag4 mice did not vary from B6-derived T CD8 . These results indicate that the avidity and function of epitope IVspecific T CD8 does not change significantly as tumors progress in RIP1-Tag4 mice, although the frequency of T CD8 that can be recruited decreases with age ( Fig. 1 ).
Discussion
Differences in the effect of tolerance toward two distinct T Ag epitopes
The overall goal of this study was to determine the extent to which peripheral tolerance affects the ability to recruit T CD8 specific for two immunodominant T Ag epitopes derived from a single oncogenic protein and whether control of spontaneous tumor growth correlates with the presence of one or both of these T CD8 populations. Our results demonstrate that tumor progression in RIP1-Tag4 mice can be controlled for the natural lifespan by targeting T CD8 specific for the single immunodominant K b -restricted epitope IV only if mice are immunized at the time of initial oncogene expression. Control of tumor development is associated with the persistence of functional epitope IV-specific T CD8 in the peripheral lymphoid organs as well as in the pancreas. Despite the persistence of epitope IV-specific T CD8 in these mice, T CD8 to a second T Ag epitope, the Db-restricted epitope I, are deleted or anergized during the early stages of tumor development as a result of their interaction with the endogenous T Ag, even when the precursor frequency is dramatically increased by the addition of epitope I-specific TCR transgenic T cells. Thus, the kinetics of tolerance is epitope-dependent, even though both epitopes are derived from the same protein.
The finding that complete T CD8 tolerance toward epitope I occurs despite only partial loss of responsiveness to epitope IV is consistent with a previous study using a different line of SV40 T Ag transgenic mice in which epitope I-specific T CD8 were shown to be more rapidly tolerized by the endogenous T Ag than epitope IV-specific T CD8 . Line 501 mice express T Ag from the ␣-amylase promoter, resulting in the formation of osteosarcomas around 1 year of age (44) . Similar to RIP1-Tag4 mice, T CD8 specific for both T Ag epitopes are initially detected following immunization of young 501 mice (6), but these mice become tolerant to epitope I by 6 mo of age when high levels of T Ag expression are detected. Epitope IV-specific T CD8 were efficiently recruited in 501 mice at 6 mo of age, but unlike the present study these cells were eventually tolerized following the appearance of tumors. One possible mechanism to explain the early loss of epitope I-specific T CD8 in these two different T Ag transgenic mouse models is that a difference in the T CD8 precursor frequency specific for epitopes I and IV may lead to more rapid loss of epitope I responsiveness. This suggestion is based on the finding that epitope IV-specific T CD8 accumulate at higher levels than epitope I-specific T CD8 in both B6 and RIP1-Tag4 mice following immunization with wild-type T Ag. Whether the magnitude of the response can be attributed to differences in the naive precursor frequency or to other mechanisms that control immunodominance remains to be determined. Our experiments here tested this possibility by seeding in large numbers of TCR-I T cells to increase the naive precursor frequency as well as the frequency of responder cells following immunization. In both cases, the epitope I-specific T CD8 were lost rapidly from the RIP1-Tag4 hosts, suggesting that the differential tolerance observed is not explained simply by the presence of fewer epitope I-specific T CD8 . Rather, our data support a model in which T CD8 specific for epitope I may be more susceptible to peripheral tolerance than T CD8 specific for epitope IV. Some factors that have been shown to contribute to peripheral T cell tolerance include the level of Ag expression (45, 46) , lack of CD4 ϩ T cell help (47) , and the avidity of self-reactive T cells (7) . Because both epitopes are derived from the same protein, it is unlikely that protein levels contribute toward this difference. Epitope I, however, is known to form highly stable complexes with Db (48), perhaps leading to prolonged high level presentation in vivo that results in more rapid deletion of the responding T cells. Whether endogenous T cells specific for epitopes I and IV from RIP1-Tag4 mice have comparable avidities is unknown.
A unique finding in this study is that a proportion of epitope IV-specific T CD8 survive the effects of peripheral tolerance in RIP1-Tag4 mice even after the appearance of tumors. This contrasts with other models of T Ag-induced spontaneous cancer in which epitope IV-specific T CD8 are eventually tolerized in mice with progressively growing tumors (6, 21) . Epitope IV-specific T CD8 are apparently deleted from the repertoire of line 501 mice developing osteosarcomas, as they are undetectable following immunization of tumor-bearing animals but respond to immunization in age-matched littermates without tumors (6) . This difference might be due to contrasting properties of osteosarcomas developing in 501 mice and insulinomas in RIP1-Tag4 mice. Tumors in 501 mice appear at a later age, grow invasively into surrounding tissues, and are metastatic (44) . In contrast, tumors in RIP1-Tag4 mice do not infiltrate surrounding tissues and do not form metastases. In addition, T Ag is expressed in multiple tissues in 501 mice, whereas expression is localized to the pancreatic ␤ cells in RIP1-Tag4 mice.
A different scenario is observed when a silent T Ag transgene, expressed from the ␤-actin/␤-globin promoter, is activated and leads to sporadic tumor formation in various tissues (21) . In this case, epitope IV-specific T CD8 appear to be rendered noncytolytic by the tumor environment, perhaps due to the presence of immunosuppressive cytokines such as TGF-␤. This finding contrasts with our observation in which epitope IV-specific T CD8 remained cytotoxic even in mice with advanced-stage tumors. These differences are a reminder that unique tumor environments can differentially affect T CD8 responding to the same tumor-specific epitope and that the results cannot be generally applied to all tumor models.
Tumor progression in the presence of competent epitope IVspecific T CD8
We found no evidence that tumor progression in naive RIP1-Tag4 mice altered the quality of epitope IV-specific T CD8 , although the number of responding cells is reduced 3-fold in tumor-bearing mice vs 5-wk old mice. Indeed, epitope IV-specific T CD8 generated in tumor-bearing mice acquired in vivo killing activity and the ability to produce IFN-␥ and had a similar avidity for epitope IV peptide as those from normal B6 mice. Yet these T CD8 failed to significantly control tumor growth. A different result was obtained in mice coexpressing the lymphocytic choriomeningitis virus (LCMV) glycoprotein and T Ag from RIP in which immunization of tumor-bearing mice with LCMV was shown to provide a delay in tumor progression that waned following elimination of the virus (49) . Similar to our findings, tumor progression continued despite the presence of persisting functional T CD8 targeting the immunodominant LCMV epitope. Our findings also contrast with those from some other tumor systems (50) in which tumor-infiltrating T CD8 were impaired in their ability to effectively destroy progressing tumors due to production of immunosuppressive cytokines (51, 52) , inhibition by regulatory T cells (53) (54) (55) , induction of apoptosis (56), or failure to infiltrate existing tumors (22) . Whether T CD8 within the tumor stroma of RIP1-Tag4 mice are inhibited in situ remains to be determined.
Because epitope IV-specific T CD8 remain responsive and functional in RIP1-Tag4 mice with progressing tumors, escape from immune-mediated control of tumor progression may be related to changes in the tumor cells themselves. One such mechanism is the down-regulation of MHC class I expression, enabling tumor escape from immunosurveillance (57) (58) (59) . Extensive analysis of MHC class I expression on islet cells in RIP1-Tag4 mice by Ye et al. (60) showed that normal islets in B6 and RIP1-Tag4 mice express MHC class I, whereas insulinomas from unimmunized RIP1-Tag4 mice contained a heterogeneous population of cells that were either negative or weakly positive for MHC class I expression. This observation suggests that heterogeneity of MHC class I expression on tumor cells could limit the efficiency of immunosurveillance in 6-mo-old RIP1-Tag4 mice by preventing the recognition of T Ag-expressing tumor cells.
The basis for complete protection in RIP1-Tag4 mice immunized before but not after tumor formation may lie in the steps that lead to T Ag transformation and tumorigenesis. T Ag-expressing cells undergo immortalization with the capacity to proliferate followed by acquisition of a tumorigenic phenotype (61) . A brief interaction with activated functional T Ag-specific T CD8 can interfere with this process. Our previous studies (62) have shown that T Ag-transfected primary mouse embryo fibroblasts abort the transformation process upon a brief interaction with a T Ag-specific CTL clone. In this study we show that a portion of pancreatic islets of RIP1-Tag4 mice that were immunized at 35 days of age still contain cells positive for T Ag expression at 2 years of age, and most do not appear to be hyperplastic. The mechanism by which epitope IV-specific T CD8 suppress tumor progression in vivo could be mediated by the production of cytokines such as IFN-␥ or TNF-␣ (63, 64) . Alternatively, those cells expressing the highest levels of T Ag might be eliminated before transitioning to tumor cells. This mechanism requires sufficient levels of MHC class I expression to present T Ag epitopes to functional T CD8 , whereas escape variants arising because of low MHC class I expression would be expected to quickly advance to progressively growing tumors.
Lifelong tumor control without development of diabetes
Our results provide support for an earlier observation (18) that RIP1-Tag4 mice immunized with SV40 before endogenous T Ag expression led to long-term control of tumor progression (average lifespan of 622 days in the previous study). However, immunization with SV40 was ineffective after T Ag was expressed from the host's own ␤ cells despite the persistence of SV40-specific CTL. Although the vehicle used for immunization (SV40 vs T Ag transformed cells) differs from that in the previous study, our findings here suggest that control of tumor progression following SV40 infection of young RIP1-Tag4 mice in the previous study was likely mediated by epitope IV-specific T CD8 . A similar result was obtained recently in the related RIP1-Tag5 line of mice following immunization with soluble T Ag in the presence of CpG-containing oligonucleotides (22) , although no quantitative data on the T CD8 response was presented.
We found that long-term control of tumor development by epitope IV-specific T CD8 does not result in diabetes in RIP1-Tag4 mice, because sufficient numbers of T Ag-expressing ␤ cells survive. This is despite the persistence of functionally competent epitope IV-specific T CD8 . Thus, an equilibrium is reached in which tumor progression is controlled but organ function is maintained, an ideal scenario for tumor immunotherapy. Our results contrast with those observed in mice expressing either the glycoprotein or NP from LCMV in ␤ cells. In this case, virus infection resulted in T cell infiltration followed by diabetes due to destruction of the ␤ cells (39, 40) . Indeed, we found that T Ag-expressing cells persisted in the islets of long-term survivors. Whether continued ␤-islet cell survival in these mice is dependent on the level of T Ag expression is unknown. Defining the basis for the establishment of this equilibrium may yield new concepts for targeting immunotherapy against self-Ags.
A similar scenario has been observed in some transplantable tumor models in which immunization against a self-tumor Ag induces tumor regression without leading to autoimmunity (5, 65, 66) . Thus, the number of insulin-secreting T Ag-positive ␤ cells that remain produce enough insulin to prevent the development of diabetes. It should be pointed out that all ␤ cells in RIP1-Tag4 transgenic mice are expected to express T Ag, although the expression levels may vary (32) . In the RIP-hemagglutinin (HA) transgenic model, immunization with Flu also induces the onset of diabetes due to the activation of endogenous self-reactive T CD8 (42) . In this model, however, RIP-HA mice must be immunized before 1 wk of age to induce diabetes, because high avidity HAspecific T CD8 are eliminated by peripheral tolerance at later time points (7) . Preliminary experiments suggest that epitope IV-specific T CD8 recovered from long-term surviving RIP1-Tag4 mice have avidities similar to those derived from B6 mice. The possibility remains that the LCMV and Flu HA proteins are expressed at higher levels in the pancreas than T Ag, such that ␤ cells in these mice are more readily destroyed.
A recently published study argued against a role for immunosurveillance of spontaneous cancer (21) . That suggestion may not be generalized to all immunogenic spontaneous models of cancer (67) . Although the role of spontaneously primed T CD8 to control autochthonous tumors will continue to be debated, data presented here and by others (18, 21) argue that long-term immunosurveillance against spontaneous tumors can be effective if T cells are activated before the appearance of tumors or if the tumor-bearing host is preconditioned before immunotherapy (14, 31, 68) . A key to effective T cell-mediated therapy is to target epitopes less likely to lead to peripheral tolerance following prolonged exposure to the endogenous Ag. In addition, understanding the mechanisms by which tumor-specific T cell responses can mediate control of tumor progression without disrupting organ function will be a major advance toward developing immunotherapeutic strategies.
